Apricus Biosciences

Apricus plummets after ED drug rejection
Apricus plummets after ED drug rejection
Biopharma Dive
Apricus Biosciences
FDA
erectile dysfunction
Vitaros
Flag link:
Apricus Biosciences Sells ED Therapy Rights
Apricus Biosciences Sells ED Therapy Rights
Investopedia
Apricus Biosciences
erectile dysfunction
Ferring
Vitaros
Flag link:
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Greece
Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Greece
Cafepharma/Globe Newswire
Apricus Biosciences
Vitaros
erectile dysfunction
Greece
Flag link:
Top 6 Biopharma Movers of the Past Week
Top 6 Biopharma Movers of the Past Week
24/7 Wall St
Genocea Biosciences
OPKO Health
ContraVir
Inovio
Acadia
Apricus Biosciences
Flag link:
Apricus shares are routed after testosterone drug fails to deliver clinical benefits
Apricus shares are routed after testosterone drug fails to deliver clinical benefits
Fierce Biotech
Apricus Biosciences
testosterone
fispemifene
Flag link:
5 Big FDA Decisions Expected in September
5 Big FDA Decisions Expected in September
24/7 Wall St
FDA
rolapitant
OPKO Health
Tesaro
Zosano
ZP-Glucagon
XenoPort
XP23829
Apricus Biosciences
RayVa
Flag link:
The Success Of Addyi And Sprout May Reward Investors In Apricus Bio And Femprox
The Success Of Addyi And Sprout May Reward Investors In Apricus Bio And Femprox
Seeking Alpha
Addyi
Sprout Pharmaceuticals
female sexual dysfunction
Apricus Biosciences
Femprox
Flag link:
Apricus Biosciences And Vivus: A Potential Golden Marriage
Apricus Biosciences And Vivus: A Potential Golden Marriage
Seeking Alpha
Vivus
Apricus Biosciences
M&A
Flag link:
Apricus Biosciences granted national phase approval for Vitaros in Luxembourg
Apricus Biosciences granted national phase approval for Vitaros in Luxembourg
The Fly on the Wall
Apricus Biosciences
erectile dysfunciton
Vitaros
Luxembourg
Flag link:
Apricus' Loss Narrows in Q4
Apricus' Loss Narrows in Q4
Yahoo/Zacks.com
Apricus Biosciences
earnings
Flag link:
2014 Could Be A Transformative Year For Apricus Biosciences
2014 Could Be A Transformative Year For Apricus Biosciences
Seeking Alpha
Apricus Biosciences
Vitaros
erectile dysfunction
Femprox
female sexual dysfunction
Flag link:
Apricus Biosciences expects to announce additional Vitaros partnerships
Apricus Biosciences expects to announce additional Vitaros partnerships
The Fly on the Wall
Apricus Biosciences
Vitaros
Flag link:
Targeting An Untapped Female Sexual Dysfunction Drug Market
Targeting An Untapped Female Sexual Dysfunction Drug Market
Seeking Alpha
female sexual dysfunction
Osphena
Shionogi
flibanserin
Sprout Pharmaceuticals
bremelanotide
Palatin
Femprox
Apricus Biosciences
Flag link:
Will Big Changes At Apricus Biosciences Make It A Winning Stock?
Will Big Changes At Apricus Biosciences Make It A Winning Stock?
Seeking Alpha
Apricus Biosciences
RayVa
MycoVa
Vitaros
Femprox
Flag link:
Apricus Biosciences announces sale of non-core assets
Apricus Biosciences announces sale of non-core assets
Yahoo/Fly on the Wall
Apricus Biosciences
NitroMist
Biocodex
Totect
Flag link:
Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer
Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer
Yahoo
Apricus Biosciences
Flag link:
Apricus Biosciences buying CSO to support European sales push
Apricus Biosciences buying CSO to support European sales push
Outsourcing Pharma
CSO
M&A
Apricus Biosciences
France
Europe
contract sales
Scomedica
Flag link:
Apricus Biosciences submits response for Vitaros market application
Apricus Biosciences submits response for Vitaros market application
Yahoo/Fly on the Wall
Apricus Biosciences
Vitaros
Switzerland
erectile dysfunction
Flag link:
Apricus Biosciences granted pre-NDS meeting for Femprox
Apricus Biosciences granted pre-NDS meeting for Femprox
Yahoo/Fly on the Wall
Apricus Biosciences
Femprox
Canada
Flag link:
Apricus Biosciences Announces Poster Presentation of Femprox Phase III Clinical Data at American Urological Association Annual Meeting
Apricus Biosciences Announces Poster Presentation of Femprox Phase III Clinical Data at American Urological Association Annual Meeting
Pharmalive
Femprox
Apricus Biosciences
female sexual dysfunction
Flag link:

Pages